
Opinion|Videos|April 28, 2025
Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective
Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Communication Strategies for Treatment Decision-Making
Key Themes:
- Shared Decision-Making: Challenges in presenting complex clinical trial data to patients in time-constrained clinical settings
- Patient Education: Balancing efficacy outcomes with toxicity profiles when discussing treatment options
- Individualized Approach: Recognizing that patient preferences and knowledge vary significantly
Notable Insights:
- Dr Piotrowska: “I think the best way to do this is to try to talk about it and then give patients a little bit of time to digest and think through these options, and maybe not make a final decision in that initial visit.” She also acknowledges that clinicians bring their own biases to these conversations.
- Dr Dietrich: Notes the importance of recognizing different patient information needs, stating “Some patients are very informed...and some others are deferring more to me.” He emphasized that these discussions have become “significantly harder, both on the discussion about efficacy and the nuances of [adverse] effects.”
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.

Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.

The DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan received FDA orphan drug designation for the management of neuroendocrine carcinomas.

A growing clinical phenomenon of incidentally finding early-stage lung cancer suggests a significant gap in the current screening paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Issues CRL to 177Lu-Edotreotide for GEP-NETs
2
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
3
Expanding Options and Long-Term Data Reshape Frontline and Emerging CLL Treatment Strategies
4
Relapsed/Refractory Multiple Myeloma: Applying Real-World Evidence to CAR T-Cell Therapy
5


